Pfizer Enters into Exclusive Collaboration and License Agreement with YaoPharma

(March 30, 2026) by Pfizer Media Relations

Following its $10 billion acquisition of Metsera, Pfizer expanded its strategy in late 2025/early 2026 by collaborating with YaoPharma. The deal includes $150 million upfront for a GLP-1 drug in early development, with total milestones reaching $1.9 billion.